Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

Edward S. Kim, MD
Published: Tuesday, Nov 28, 2017



Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

According to Kim, it is important to gather a patient’s tissue to make an informed decision on the stage of the patient and the treatment options available.

Fifty-percent of patients with non-small cell lung cancer (NSCLC) will have an EGFR, ALK, ROS1, BRAF, or PD-L1 mutation. This determines whether a patient will receive chemotherapy, explains Kim.
 


Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

According to Kim, it is important to gather a patient’s tissue to make an informed decision on the stage of the patient and the treatment options available.

Fifty-percent of patients with non-small cell lung cancer (NSCLC) will have an EGFR, ALK, ROS1, BRAF, or PD-L1 mutation. This determines whether a patient will receive chemotherapy, explains Kim.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x